Skip to main content

Table 3 Serum level of VEGF in relation to the clinicopathologic features of colorectal and non-small cell lung cancers (p < 0.05 was considered significant)

From: Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis

Pathological features No. of cases VEGF concentration (pg/ml) pvaluea
Colorectal tumours 38 1,081 ± 652b  
Gender    
   Female 22 987 ± 470 0.433
   Male 16 1212 ± 841  
Tumour size    
   ≤ 5 cm 23 1134 ± 727 0.411
   > 5 cm 15 1002 ± 531  
Tumour stage grouping    
   Early stage 23 1166 ± 799 0.777
   Late stage 15 954 ± 303  
Metastasis    
   No 27 1132 ± 749 0.910
   Yes 11 961 ± 304  
VEGF 23 kDa    
   Positive 25 1190 ± 752 0.207
   Negative 13 875 ± 330  
VEGF 26 kDa    
   Positive 26 1125 ± 720 0.742
   Negative 12 989 ± 486  
Lung tumours 18 1,251 ± 568  
Gender    
   Female 10 1297 ± 509 0.374
   Male 8 1194 ± 666  
Tumour size    
   ≤ 5 cm 7 1304 ± 661 0.762
   > 5 cm 11 1217 ± 532  
Tumour stage grouping    
   Early stage 2 716 ± 666 0.206
   Late stage 16 1318 ± 541  
Metastasis    
   Yes 8 1125 ± 655 0.556
   No 10 1331 ± 522  
VEGF 23 kDa    
   Positive 16 1190 ± 574 0.160
   Negative 2 1741 ± 9.8  
VEGF 26 kDa    
   Positive 16 1224 ± 590 0.482
   Negative 2 1468 ± 395  
  1. a Mann-Whitney test, bmean ± SD